---
provider: openscientist
model: openscientist-autonomous
cached: false
start_time: '2026-10-19T00:30:02.657549'
end_time: '2026-10-19T00:47:13.448023'
duration_seconds: 1030.79
template_file: templates/disease_pathophysiology_research.md
template_sha: "1e7ea4ee817acfe1dda5f77fafe6f2e8b5927666"
template_variables:
  disease_name: ROSAH Syndrome
  mondo_id: MONDO:0013999
  category: Mendelian
provider_config:
  timeout: 3600
  max_retries: 3
  parameters:
    allowed_domains: []
    max_iterations: 5
    use_hypotheses: false
    investigation_mode: autonomous
    poll_interval: 30
    timeout: 3600
    save_artifacts: true
    artifact_max_bytes: 5242880
fell_back: true
requested_provider: falcon
provider_attempts:
- provider: falcon
  succeeded: false
  error_type: ProviderAuthError
  status_code: 403
  remedy: the API key is missing, invalid, or lacks access to this endpoint
  retryable: false
- provider: openscientist
  succeeded: true
citation_count: 24
reference_validation:
  total_references: 24
  verified: 24
  not_found: 0
  unverifiable: 0
  confabulation_rate: 0.0
  relevance_assessed: 24
  on_topic: 17
  off_topic: 1
  off_topic_references:
  - PMID:31075211
  needs_review: true
  validator_version: 0.3.0
term_validation:
  total_terms: 38
  verified: 35
  not_found: 1
  obsolete: 0
  unverifiable: 2
  confabulation_rate: 0.028
  labels_checked: 14
  labels_matching: 3
  labels_mismatched: 10
  mislabelled_terms:
  - term_id: HP:0040049
    reported_labels:
    - Clinical sign
    ontology_label: Macular edema
  - term_id: HP:0000501
    reported_labels:
    - Clinical sign
    ontology_label: Glaucoma
  - term_id: HP:0001744
    reported_labels:
    - Physical manifestation
    ontology_label: Splenomegaly
  - term_id: HP:0000970
    reported_labels:
    - Clinical sign
    ontology_label: Anhidrosis
  - term_id: HP:0002076
    reported_labels:
    - Symptom
    ontology_label: Migraine
  - term_id: HP:0001945
    reported_labels:
    - Symptom
    ontology_label: Fever
  - term_id: HP:0002758
    reported_labels:
    - Clinical sign
    ontology_label: Osteoarthritis
  - term_id: HP:0002719
    reported_labels:
    - Clinical sign
    ontology_label: Recurrent infections
  - term_id: HP:0000988
    reported_labels:
    - Clinical sign
    ontology_label: Skin rash
  - term_id: UBERON:0000970
    reported_labels:
    - eye
    - Primary organs:** **eye
    ontology_label: eye
  labels_variant: 1
  unresolved_terms:
  - HP:0002452
  unresolvable_prefixes:
  - ORPHA
  needs_review: true
  adapter: 'ols:'
  validator_version: 0.4.5
artifact_count: 2
artifact_sources:
  openscientist_artifacts_zip: 2
artifacts:
- filename: final_report.html
  path: ROSAH_Syndrome-deep-research-openscientist_artifacts/final_report.html
  media_type: text/html
  source: openscientist_artifacts_zip
  data_storage_id: null
  description: OpenScientist final report
- filename: final_report.pdf
  path: ROSAH_Syndrome-deep-research-openscientist_artifacts/final_report.pdf
  media_type: application/pdf
  source: openscientist_artifacts_zip
  data_storage_id: null
  description: OpenScientist final report
---

## Question

# Disease Characteristics Research Template

## Target Disease
- **Disease Name:** ROSAH Syndrome
- **MONDO ID:** MONDO:0013999 (if available)
- **Category:** Mendelian

## Research Objectives

Please provide a comprehensive research report on **ROSAH Syndrome** covering all of the
disease characteristics listed below. This report will be used to populate a disease knowledge
base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, **suggested databases/resources** are listed. These are the first places
you should search for information on each topic.

---

### 1. Disease Information
> **Search first:** OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

- What is the disease? Provide a concise overview.
- What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
- What are the common synonyms and alternative names?
- Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

### 2. Etiology

- **Disease Causal Factors**: What are the primary causes? (genetic, environmental, infectious, mechanistic)
- **Risk Factors**:
  > **Search first:** PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
  - Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  - Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
- **Protective Factors**:
  > **Search first:** PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
  - Genetic protective factors (protective variants, modifier alleles)
  - Environmental protective factors (diet, lifestyle, exposures that reduce risk)
- **Gene-Environment Interactions**: How do genetic and environmental factors interact to influence disease?
  > **Search first:** CTD, PubMed, PheGenI, GxE databases

### 3. Phenotypes
> **Search first:** HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide:
- **Phenotype type**: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
  > For symptoms/signs: HPO, OMIM, Orphanet, PubMed
  > For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed
  > For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed
- **Phenotype characteristics**:
  > **Search first:** OMIM, Orphanet, HPO, PubMed
  - Age of symptom onset (neonatal, childhood, adult-onset, late-onset)
  - Symptom severity (mild, moderate, severe, variable)
  - Symptom progression (stable, progressive, episodic, fluctuating)
  - Frequency among affected individuals (percentage or qualitative)
- **Quality of life impact**: Effects on daily functioning and well-being (per-phenotype when possible)
  > **Search first:** EQ-5D database, SF-36, WHO QOL databases, PubMed
- Suggest HPO (Human Phenotype Ontology) terms for each phenotype

### 4. Genetic/Molecular Information

- **Causal Genes**: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)
  > **Search first:** OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
- **Pathogenic Variants**:
  - Affected genes (gene symbols, HGNC IDs)
    > **Search first:** OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  - Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines)
    > **Search first:** ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  - Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  - Allele frequency in population databases
    > **Search first:** gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  - Somatic vs germline origin
    > **Search first:** COSMIC (somatic), ClinVar, ICGC, TCGA
  - Functional consequences (loss of function, gain of function, dominant negative)
- **Modifier Genes**: Genes that modify disease severity or expression
- **Epigenetic Information**: DNA methylation, histone modifications, chromatin changes affecting disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Chromosomal Abnormalities**: Large-scale genetic changes (aneuploidy, translocations, inversions)
  > **Search first:** DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

### 5. Environmental Information

- **Environmental Factors**: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)
  > **Search first:** CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
- **Lifestyle Factors**: Behavioral factors (smoking, diet, exercise, alcohol consumption)
  > **Search first:** CDC databases, WHO, PubMed, NHANES
- **Infectious Agents**: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)
  > **Search first:** NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

### 6. Mechanism / Pathophysiology

**Present this section as an ordered causal chain first, then the detail below.**
Open with a numbered sequence of mechanistic steps running from the initiating
lesion (mutation, exposure, infection) to the clinical manifestation, one step per
line, each naming what it causes next. State the causal verb explicitly ("leads
to", "results in") and say where a step is inferred rather than demonstrated.
Where the mechanism branches, show the branch. The categories below are a
checklist of what to cover within those steps, not the organizing structure —
a step may draw on several of them, and a category may contribute to several
steps.

- **Molecular Pathways**: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)
  > **Search first:** KEGG, Reactome, WikiPathways, PathBank, BioCyc
- **Cellular Processes**: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)
  > **Search first:** Gene Ontology (GO), Reactome, KEGG, PubMed
- **Protein Dysfunction**: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)
  > **Search first:** UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
- **Metabolic Changes**: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)
  > **Search first:** KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
- **Immune System Involvement**: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)
  > **Search first:** ImmPort, Immunome Database, IEDB, Gene Ontology
- **Tissue Damage Mechanisms**: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)
  > **Search first:** PubMed, Gene Ontology, Reactome
- **Biochemical Abnormalities**: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)
  > **Search first:** BRENDA, UniProt, KEGG, OMIM, PubMed
- **Epigenetic Changes**: DNA methylation, histone modifications affecting gene expression in disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Molecular Profiling** (if available):
  - Transcriptomics/gene expression changes
    > **Search first:** GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  - Proteomics findings
    > **Search first:** PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  - Metabolomics signatures
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB, METLIN
  - Lipidomics alterations
    > **Search first:** LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  - Genomic structural features
    > **Search first:** UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
- **Advanced Technologies** (if applicable):
  - Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity)
    > **Search first:** Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  - Spatial transcriptomics findings
    > **Search first:** GEO, Spatial Research, Vizgen, 10x Genomics data
  - Multi-omics integration results
    > **Search first:** TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  - Functional genomics screens (CRISPR, RNAi)
    > **Search first:** DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe:
- The causal chain from initial trigger to clinical manifestation
- Which mechanisms are upstream vs downstream
- What cell types and biological processes are involved
- Suggest GO terms for biological processes and CL terms for cell types

### 7. Anatomical Structures Affected

- **Organ Level**:
  - Primary organs directly affected
  - Secondary organ involvement (complications, secondary effects)
  - Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)
  > **Search first:** Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
- **Tissue and Cell Level**:
  - Specific tissue types affected (epithelial, connective, muscle, nervous)
  - Specific cell populations targeted (with Cell Ontology terms)
  > **Search first:** Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
- **Subcellular Level**:
  - Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)
  > **Search first:** Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
- **Localization**:
  - Specific anatomical sites (with UBERON terms)
    > **Search first:** FMA, Uberon, NeuroNames (for brain), SNOMED CT
  - Lateralization (unilateral, bilateral, asymmetric)
    > **Search first:** HPO, clinical literature, imaging databases

### 8. Temporal Development

- **Onset**:
  - Typical age of onset (congenital, pediatric, adult, geriatric)
  - Onset pattern (acute, subacute, chronic, insidious)
  > **Search first:** OMIM, Orphanet, HPO, PubMed
- **Progression**:
  - Disease stages (early, intermediate, advanced, end-stage)
    > **Search first:** Cancer Staging Manual (AJCC), WHO classifications, PubMed
  - Progression rate (rapid, slow, variable)
  - Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  - Disease duration (self-limited, chronic lifelong)
  > **Search first:** Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
- **Patterns**:
  - Remission patterns (spontaneous, treatment-induced)
    > **Search first:** Clinical trial databases, disease registries, PubMed
  - Critical periods (time windows of vulnerability or opportunity for intervention)
    > **Search first:** PubMed, developmental biology databases, clinical guidelines

### 9. Inheritance and Population

- **Epidemiology**:
  - Prevalence (cases per 100,000 at given time)
  - Incidence (new cases per 100,000 per year)
  > **Search first:** Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
- **For Genetic Etiology**:
  - Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic)
    > **Search first:** OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  - Penetrance (complete, incomplete, age-dependent)
    > **Search first:** ClinVar, OMIM, PubMed, ClinGen
  - Expressivity (variable, consistent)
    > **Search first:** OMIM, ClinVar, PubMed
  - Genetic anticipation (increasing severity in successive generations)
    > **Search first:** OMIM, PubMed (especially for repeat expansion disorders)
  - Germline mosaicism
    > **Search first:** ClinVar, OMIM, genetic counseling literature, PubMed
  - Founder effects (population-specific mutations)
    > **Search first:** gnomAD, population genetics databases, PubMed
  - Consanguinity role
    > **Search first:** OMIM, population studies, genetic counseling resources
  - Carrier frequency
    > **Search first:** gnomAD, carrier screening databases, GeneReviews, GTR
- **Population Demographics**:
  - Affected populations (ethnic or demographic groups with higher prevalence)
    > **Search first:** gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  - Geographic distribution (endemic areas, regional variation)
    > **Search first:** WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  - Geographic distribution of specific variants
  - Sex ratio (male:female)
    > **Search first:** Disease registries, OMIM, PubMed, epidemiological databases
  - Age distribution of affected individuals
    > **Search first:** CDC, disease registries, SEER, Orphanet

### 10. Diagnostics

- **Clinical Tests**:
  - Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays)
    > **Search first:** LOINC, LabTests Online, PubMed
  - Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers)
    > **Search first:** FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  - Imaging studies (X-ray, CT, MRI, PET, ultrasound)
    > **Search first:** RadLex, DICOM, Radiopaedia, imaging databases
  - Functional tests (pulmonary function, cardiac stress tests)
    > **Search first:** LOINC, clinical guidelines, PubMed
  - Electrophysiology (EEG, EMG, ECG, nerve conduction studies)
    > **Search first:** LOINC, clinical neurophysiology databases, PubMed
  - Biopsy findings (histopathology, immunohistochemistry)
    > **Search first:** SNOMED CT, College of American Pathologists resources, PubMed
  - Pathology findings (microscopic examination)
    > **Search first:** SNOMED CT, Digital Pathology databases, PubMed
- **Genetic Testing**:
  > **Search first:** GTR (Genetic Testing Registry), GeneReviews, ClinGen
  - Overview of recommended genetic testing approach
  - Whole genome sequencing (WGS) utility
    > **Search first:** GTR, ClinVar, GEL (Genomics England), gnomAD
  - Whole exome sequencing (WES) utility
    > **Search first:** GTR, ClinVar, OMIM, GeneMatcher
  - Gene panels (which panels, which genes)
    > **Search first:** GTR, ClinVar, laboratory-specific databases
  - Single gene testing
    > **Search first:** GTR, ClinVar, OMIM, GeneReviews
  - Chromosomal microarray (CMA)
    > **Search first:** DECIPHER, ClinVar, dbVar, ECARUCA
  - Karyotyping
    > **Search first:** Chromosome Abnormality Database, ClinVar, cytogenetics resources
  - FISH
    > **Search first:** ClinVar, cytogenetics databases, PubMed
  - Mitochondrial DNA testing
    > **Search first:** MITOMAP, MSeqDR, ClinVar, GTR
  - Repeat expansion testing
    > **Search first:** GTR, ClinVar, repeat expansion databases, PubMed
- **Omics-Based Diagnostics** (if applicable):
  - RNA sequencing / transcriptomics
    > **Search first:** GEO, ArrayExpress, GTEx, RNA-seq databases
  - Proteomics
    > **Search first:** PRIDE, ProteomeXchange, FDA Biomarker database
  - Metabolomics
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB
  - Epigenomics
    > **Search first:** GEO, ENCODE, Roadmap Epigenomics, MethBase
  - Liquid biopsy
    > **Search first:** COSMIC, ClinVar, liquid biopsy databases, PubMed
- **Clinical Criteria**:
  - Standardized diagnostic criteria (DSM, ICD, society guidelines)
    > **Search first:** DSM-5, ICD-11, clinical society guidelines, UpToDate
  - Differential diagnosis (other conditions to rule out, with distinguishing features)
    > **Search first:** DynaMed, UpToDate, clinical decision support systems
- **Screening**:
  - Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening)
    > **Search first:** ACMG recommendations, CDC newborn screening, GTR

### 11. Outcome/Prognosis

- **Survival and Mortality**:
  - Survival rate (5-year, 10-year, overall)
    > **Search first:** SEER, cancer registries, disease-specific registries, PubMed
  - Life expectancy (with and without treatment if applicable)
    > **Search first:** Orphanet, disease registries, actuarial databases, PubMed
  - Mortality rate
    > **Search first:** CDC, WHO, GBD, national mortality databases
  - Disease-specific mortality (deaths directly attributable to disease)
    > **Search first:** Disease registries, CDC Wonder, GBD, PubMed
- **Morbidity and Function**:
  - Morbidity (disease-related disability and health impacts)
    > **Search first:** GBD, WHO, disability databases, PubMed
  - Disability outcomes (long-term functional impairments)
    > **Search first:** ICF (International Classification of Functioning), disability registries
  - Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools)
    > **Search first:** EQ-5D database, SF-36, PROMIS, PubMed
- **Disease Course**:
  - Complications (secondary problems: infections, organ failure, etc.)
    > **Search first:** ICD codes, disease registries, clinical databases, PubMed
  - Recovery potential (likelihood and extent of recovery, with vs without treatment)
    > **Search first:** Natural history studies, rehabilitation databases, PubMed
- **Prediction**:
  - Prognostic factors (age, disease severity, biomarkers, treatment response)
    > **Search first:** Prognostic models databases, clinical calculators, PubMed
  - Prognostic biomarkers (molecular markers predicting disease course)
    > **Search first:** FDA Biomarker database, PubMed, cancer prognostic databases

### 12. Treatment

- **Pharmacotherapy**:
  - Pharmacological treatments (drug names, drug classes, mechanisms of action)
    > **Search first:** DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  - Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity)
    > **Search first:** PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
- **Advanced Therapeutics**:
  - Gene therapy (viral vectors, CRISPR, gene replacement, gene editing)
    > **Search first:** ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  - Cell therapy (stem cell transplant, CAR-T, cellular therapeutics)
    > **Search first:** ClinicalTrials.gov, FDA cell therapy database, FACT standards
  - RNA-based therapies (ASOs, siRNA, mRNA therapies)
    > **Search first:** ClinicalTrials.gov, FDA approvals, PubMed
  - Targeted therapies (treatments directed at specific molecular targets)
    > **Search first:** My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  - Immunotherapies (checkpoint inhibitors, monoclonal antibodies)
    > **Search first:** Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
- **Surgical and Interventional**:
  - Surgical interventions (types of surgery, timing, outcomes)
    > **Search first:** CPT codes, surgical registries, clinical guidelines, PubMed
- **Supportive and Rehabilitative**:
  - Supportive care (symptom management, pain control, nutrition)
    > **Search first:** Clinical guidelines, Cochrane Library, PubMed
  - Rehabilitation (physical therapy, occupational therapy, speech therapy)
    > **Search first:** Rehabilitation medicine databases, clinical guidelines, PubMed
- **Experimental**:
  - Experimental treatments in clinical trials (with NCT identifiers if available)
    > **Search first:** ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
- **Treatment Outcomes**:
  - Treatment response rates
    > **Search first:** Clinical trial databases, FDA reviews, systematic reviews, PubMed
  - Side effects and adverse events
    > **Search first:** FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
- **Treatment Strategy**:
  - Treatment algorithms (clinical pathways, decision trees)
    > **Search first:** Clinical practice guidelines, NCCN Guidelines, UpToDate
  - Combination therapies
    > **Search first:** ClinicalTrials.gov, treatment guidelines, PubMed
  - Personalized medicine approaches (genotype-guided treatment)
    > **Search first:** My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

### 13. Prevention

- **Prevention Levels**:
  - Primary prevention (preventing disease occurrence: vaccination, risk factor modification)
    > **Search first:** CDC, WHO, USPSTF recommendations, Cochrane Library
  - Secondary prevention (early detection and treatment: screening programs, early intervention)
    > **Search first:** USPSTF, CDC screening guidelines, WHO
  - Tertiary prevention (preventing complications in those with disease)
    > **Search first:** Clinical guidelines, disease management protocols, PubMed
- **Immunization**: Vaccine strategies (if applicable)
  > **Search first:** CDC vaccine schedules, WHO immunization, FDA vaccine database
- **Screening and Early Detection**:
  - Screening programs (population-based: newborn screening, cancer screening)
    > **Search first:** CDC screening programs, USPSTF, cancer screening databases
  - Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing)
    > **Search first:** ACMG recommendations, ACOG guidelines, GTR
  - Risk stratification (identifying high-risk individuals for targeted prevention)
    > **Search first:** Risk prediction models, clinical calculators, PubMed
- **Behavioral Interventions**: Lifestyle modifications to reduce risk
  > **Search first:** CDC, WHO, behavioral intervention databases, Cochrane Library
- **Counseling**: Genetic counseling (risk assessment, family planning guidance)
  > **Search first:** NSGC resources, ACMG guidelines, GeneReviews
- **Public Health**:
  - Public health interventions (sanitation, vector control, health education)
    > **Search first:** CDC, WHO, public health databases, PubMed
  - Environmental interventions (reducing environmental risk factors)
    > **Search first:** EPA databases, WHO environmental health, PubMed
- **Prophylaxis**: Preventive medications or procedures
  > **Search first:** Clinical guidelines, FDA approvals, PubMed

### 14. Other Species / Natural Disease

- **Taxonomy**: Species affected (with NCBI Taxon identifiers)
  > **Search first:** NCBI Taxonomy
- **Breed**: Specific breeds affected (with VBO identifiers if applicable)
  > **Search first:** VBO (Vertebrate Breed Ontology)
- **Gene**: Orthologous genes in other species (with NCBI Gene IDs)
  > **Search first:** NCBI Gene
- **Natural Disease**:
  - Naturally occurring disease in other species (companion animals, wildlife)
    > **Search first:** OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  - Veterinary relevance and importance in animal health
    > **Search first:** OMIA, veterinary databases, PubMed
- **Comparative Biology**:
  - Comparative pathology (similarities and differences across species)
    > **Search first:** OMIA, comparative pathology databases, PubMed
  - Evolutionary conservation of disease mechanisms
    > **Search first:** HomoloGene, OrthoMCL, Alliance of Genome Resources
- **Transmission** (if applicable):
  - Zoonotic potential
    > **Search first:** CDC zoonotic diseases, WHO zoonoses, GIDEON
  - Cross-species susceptibility
    > **Search first:** NCBI Taxonomy, veterinary databases, PubMed

### 15. Model Organisms

- **Model Types**:
  - Model organism type (mammalian, invertebrate, cellular, in vitro)
    > **Search first:** Alliance of Genome Resources, model organism databases
  - Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs)
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  - Induced models (drug treatment, surgical intervention, environmental manipulation)
    > **Search first:** MGI, model organism databases, PubMed
- **Genetic Models**:
  - Types available (knockout, knock-in, transgenic, conditional, humanized)
    > **Search first:** MGI, IMPC, KOMP, EuMMCR, IMSR
- **Model Characteristics**:
  - Phenotype recapitulation (how well model reproduces human disease features)
    > **Search first:** Model organism databases, comparative studies, PubMed
  - Model limitations (aspects of human disease not captured)
    > **Search first:** Model organism databases, PubMed, review articles
- **Applications**:
  - Research applications (what aspects of disease can be studied)
    > **Search first:** Model organism databases, PubMed
- **Resources**:
  - Model databases
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

---

## Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic and clinical claims
- Prioritize recent reviews and landmark papers
- Include direct quotes from abstracts where possible to support key statements
- Distinguish evidence source types: human clinical, model organism, in vitro, computational

## Output Format

Structure your response as a comprehensive narrative organized by the sections above.
For each section, provide:
- Factual content with specific details (numbers, percentages, gene names, variant nomenclature)
- Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable
- Evidence citations with PMIDs
- Direct quotes from abstracts to support key claims
- Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with:
- Pathophysiology descriptions with causal chains
- Gene/protein annotations (HGNC, GO terms)
- Phenotype associations (HP terms) with frequencies
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Treatment annotations (NCIT terms)
- Evidence items with PMIDs and exact abstract quotes
- Epidemiology, prognosis, diagnostic, and prevention information
- Animal model descriptions with phenotype recapitulation details


## Output

# ROSAH Syndrome — Comprehensive Disease Characteristics Report

**Disease:** ROSAH Syndrome (Retinal dystrophy, Optic nerve edema, Splenomegaly, Anhidrosis, and Headache)
**MONDO:** MONDO:0013999 · **OMIM:** #614979 · **Orphanet:** ORPHA:313800 · **Causal gene:** *ALPK1* (HGNC:20917)

---

## Summary

ROSAH syndrome is an ultra-rare, autosomal dominant **systemic autoinflammatory disease** caused by heterozygous gain-of-function missense variants in *ALPK1* (alpha-kinase 1). First delineated in 2019 in five unrelated families, the syndrome is named for its cardinal features — **R**etinal dystrophy, **O**ptic nerve edema, **S**plenomegaly, **A**nhidrosis, and **H**eadache — but is now understood to be a far broader multisystem inflammatory disorder. The defining molecular lesion is a recurrent variant, c.710C>T (p.Thr237Met), with a second recurrent allele p.Tyr254Cys and additional rarer variants (p.Ser277Phe, p.His735Pro, p.Thr237Ala). Mechanistically, wild-type ALPK1 is a cytosolic innate-immune receptor that senses the bacterial metabolite ADP-heptose and signals through TIFA–TRAF6 to activate NF-κB. The ROSAH variants are **neomorphic**: they alter the kinase's ligand specificity so it becomes aberrantly activated by endogenous host nucleotide sugars (e.g., UDP-mannose, ADP-ribose), producing constitutive NF-κB plus type I/II interferon signaling in the absence of any infection.

Clinically, the disease presents in **early childhood** with near-universal, frequently blinding bilateral ocular disease (optic disc edema, cone-rod retinal dystrophy resembling retinitis pigmentosa, low-grade uveitis/vitritis, and macular edema) accompanied by variable systemic features: splenomegaly (often with cytopenias), anhidrosis/hypohidrosis, migrainous headache, short dental roots, recurrent fever, deforming arthritis, premature basal-ganglia/brainstem mineralization on MRI, and a risk of AA (reactive) amyloidosis with renal failure. Expressivity is strikingly variable even within a single family; some individuals (notably with p.Thr237Ala) have a predominantly or exclusively ocular phenotype.

Therapeutically, cytokine blockade — particularly **IL-6 receptor inhibition with tocilizumab** — best controls systemic and intraocular inflammation and can reverse macular edema and optic-disc swelling, but **retinal/optic neurodegeneration frequently progresses despite immunosuppression**, suggesting a degenerative component partly uncoupled from controllable inflammation. The first selective ALPK1 inhibitor, **DF-003**, has been designed for oral dosing and is advancing toward the clinic. The same gene, mutated somatically at a different residue (p.Val1092Ala), drives the skin tumors spiradenoma and spiradenocarcinoma, placing ROSAH within an *ALPK1*/NF-κB "gain-of-function" allelic series.

---

## Section 1 — Disease Information

**Overview.** ROSAH syndrome is a monogenic, autosomal dominant, systemic autoinflammatory disorder with prominent ophthalmologic involvement. Although the acronym (Retinal dystrophy, Optic nerve edema, Splenomegaly, Anhidrosis, Headache) captures the cardinal features originally described, the condition is now recognized as a broad autoinflammatory disease with ocular, hematologic, neurologic, dermatologic, dental, rheumatologic, and renal manifestations.

**Key identifiers (verified via EBI OLS / MONDO and mygene.info):**

| Resource | Identifier |
|---|---|
| MONDO | MONDO:0013999 ("retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis, and migraine headache syndrome") |
| OMIM (phenotype) | #614979 |
| Orphanet | ORPHA:313800 |
| UMLS | C4749914 |
| GARD | 0017411 |
| MedGen | 1662266 |
| Causal gene *ALPK1* | HGNC:20917; NCBI Gene 80216; Ensembl ENSG00000073331; gene OMIM 607347; UniProt Q96QP1; cytoband **4q25** |

**Synonyms / alternative names:** ROSAH syndrome; Retinal dystrophy–optic nerve edema–splenomegaly–anhidrosis–headache syndrome; ALPK1-associated autoinflammatory disease. A related "ROSAH-like" presentation restricted to ophthalmologic features has been reported ([PMID: 39847428](https://pubmed.ncbi.nlm.nih.gov/39847428/)).

**Information source.** Knowledge for this entry is derived from **aggregated disease-level resources** (OMIM, Orphanet, MONDO) combined with **individual-patient clinical reports and cohorts** (e.g., the n=27 cohort of Kozycki et al. 2022 and numerous case series). It is not derived from a single EHR dataset.

---

## Section 2 — Etiology

**Primary cause — genetic.** ROSAH is caused by heterozygous **gain-of-function missense variants in *ALPK1***. The founding variant c.710C>T (p.Thr237Met) segregated with disease across five unrelated families ([PMID: 30967659](https://pubmed.ncbi.nlm.nih.gov/30967659/)). The disorder is autosomal dominant with variable expressivity.

> *"We found the heterozygous missense variant in the ɑ-kinase gene, ALPK1, (c.710C>T, [p.Thr237Met]), segregated with disease in all five families."* — [PMID: 30967659](https://pubmed.ncbi.nlm.nih.gov/30967659/)

**Genetic risk factors.** The disease is essentially monogenic; the causal alleles are the risk factors. Recurrent variants: **p.Thr237Met** (most common) and **p.Tyr254Cys**; additional reported alleles include **p.Ser277Phe**, **p.His735Pro**, and **p.Thr237Ala** (the latter associated with a milder, largely ocular phenotype). No susceptibility loci or polygenic contributions have been defined.

**Environmental / modifier factors.** No environmental exposure is required to cause disease. However, the **inflammatory context modulates the pathway**: IFN-γ "licenses" (primes/amplifies) the ALPK1/TIFA axis in human monocytes ([PMID: 39868044](https://pubmed.ncbi.nlm.nih.gov/39868044/)), and concurrent gram-negative infection (supplying ADP-heptose) could in principle further activate even wild-type ALPK1. These represent plausible gene-environment / cytokine-context interactions that may contribute to episodic flares and variable expressivity, though this remains inferred rather than demonstrated in patients.

**Protective factors.** None established. No protective alleles or lifestyle factors are known for this ultra-rare Mendelian disease.

---

## Section 3 — Phenotypes

ROSAH has a near-universal, early-onset ocular core with variable multisystem involvement. Onset is typically **pediatric (early childhood)**; penetrance for ocular disease appears high/near-complete, but expressivity varies even within families.

| Phenotype | Type | HPO suggestion | Frequency / notes |
|---|---|---|---|
| Bilateral optic disc / nerve edema | Clinical sign | HP:0000543 (optic disc edema) | Near-universal; often presenting feature |
| Cone-rod retinal dystrophy (RP-like) | Clinical sign | HP:0000541 / HP:0000510 | Near-universal; progressive; rod function often more reduced than cone ([PMID: 41046116](https://pubmed.ncbi.nlm.nih.gov/41046116/)) |
| Low-grade uveitis / vitritis, vitreous opacities | Clinical sign | HP:0000554 (uveitis) | Common; persistent vitreous inflammatory opacities |
| Macular edema | Clinical sign | HP:0040049 | Common; may respond to steroid/anti-VEGF/IL-6 blockade |
| Progressive vision loss / blindness | Symptom | HP:0000618 / HP:0000572 | Major morbidity driver |
| Glaucoma / acute angle-closure (short axial length) | Clinical sign | HP:0000501 | Reported subset ([PMID: 41880066](https://pubmed.ncbi.nlm.nih.gov/41880066/)) |
| Keratoconus, dry eye | Clinical sign | HP:0000563 / HP:0000517 | Newly described ocular-surface features ([PMID: 41880066](https://pubmed.ncbi.nlm.nih.gov/41880066/)) |
| Splenomegaly | Physical manifestation | HP:0001744 | Characteristic; often with cytopenias/pancytopenia (HP:0001876) |
| Anhidrosis / hypohidrosis | Clinical sign | HP:0000970 | Characteristic |
| Headache / migraine | Symptom | HP:0002076 | Common; sometimes with meningeal enhancement |
| Short / abnormal dental roots | Physical manifestation | HP (dental root anomaly) | Characteristic dental feature |
| Recurrent fever | Symptom | HP:0001945 | Inflammatory feature |
| Deforming arthritis / arthralgia | Clinical sign | HP:0002758 | Inflammatory feature |
| Premature basal-ganglia/brainstem mineralization | Imaging/laboratory | HP:0002452 (basal ganglia calcification) | On MRI ([PMID: 35868845](https://pubmed.ncbi.nlm.nih.gov/35868845/)) |
| AA (reactive) amyloidosis → renal failure | Laboratory/clinical | HP:0011035 / HP:0000121 | Serious complication ([PMID: 41880066](https://pubmed.ncbi.nlm.nih.gov/41880066/)) |
| Recurrent infections | Clinical sign | HP:0002719 | Reported subset |
| Urticaria | Clinical sign | HP:0000988 | Listed among MONDO features |

> *"Nearly all patients exhibited at least one feature consistent with inflammation including recurrent fever, headaches with meningeal enhancement and premature basal ganglia/brainstem mineralisation on MRI, deforming arthritis and AA amyloidosis."* — [PMID: 35868845](https://pubmed.ncbi.nlm.nih.gov/35868845/)

> *"The clinical manifestations were relatively homogeneous, prominently presenting with juvenile onset oculopathy and splenomegaly."* — [PMID: 31939038](https://pubmed.ncbi.nlm.nih.gov/31939038/)

**Quality-of-life impact.** Progressive, often irreversible vision loss is the dominant QoL burden. Systemic inflammation (fever, arthritis) and complications such as amyloidosis/renal failure add substantial morbidity. No formal EQ-5D/SF-36 studies exist for this rare disease.

---

## Section 4 — Genetic / Molecular Information

**Causal gene.** *ALPK1* (alpha-kinase 1), HGNC:20917, NCBI Gene 80216, Ensembl ENSG00000073331, UniProt Q96QP1, cytoband **4q25**. ALPK1 is a cytosolic serine/threonine alpha-kinase that functions as an innate-immune receptor.

**Pathogenic variants.**

| Variant (protein) | cDNA | Type | Classification | Notes |
|---|---|---|---|---|
| p.Thr237Met | c.710C>T | Missense | Pathogenic | Recurrent founding allele; multiple ancestries |
| p.Tyr254Cys | — | Missense | Pathogenic | Second recurrent allele (Kozycki 2022) |
| p.Ser277Phe | — | Missense | Likely pathogenic | Strong neomorphic activation ([PMID: 39626775](https://pubmed.ncbi.nlm.nih.gov/39626775/)) |
| p.His735Pro | — | Missense | VUS → likely pathogenic | pCS/ROSAH case ([PMID: 42640550](https://pubmed.ncbi.nlm.nih.gov/42640550/)) |
| p.Thr237Ala | — | Missense | Pathogenic | Milder, largely ocular phenotype ([PMID: 41046116](https://pubmed.ncbi.nlm.nih.gov/41046116/)) |

- **Variant class:** all reported ROSAH alleles are **missense**, clustering in/near the kinase/ligand-binding region.
- **Allele frequency:** absent/extremely rare in gnomAD (consistent with highly penetrant disease alleles).
- **Origin:** **germline** for ROSAH (de novo capable, given recurrence across diverse ancestries). The same gene mutated **somatically** at a different residue (p.Val1092Ala) causes spiradenoma ([PMID: 31101826](https://pubmed.ncbi.nlm.nih.gov/31101826/)).
- **Functional consequence:** **gain of function / neomorphic** — constitutive NF-κB activation; not loss of function.

> *"The majority of the cohort carried the p.Thr237Met mutation but we also identified a new ROSAH-associated mutation, p.Tyr254Cys."* — [PMID: 35868845](https://pubmed.ncbi.nlm.nih.gov/35868845/)

**Modifier genes / epigenetics / chromosomal abnormalities.** No specific modifier genes or epigenetic mechanisms have been established for ROSAH, and there are no associated chromosomal abnormalities (this is a single-nucleotide-variant disease). IFN-γ cytokine priming ([PMID: 39868044](https://pubmed.ncbi.nlm.nih.gov/39868044/)) acts as a functional modifier of pathway output.

---

## Section 5 — Environmental Information

ROSAH is a Mendelian disorder with no required environmental cause. Relevant non-genetic contributors are **inflammatory/cytokine context** rather than toxins or lifestyle:

- **Infectious / PAMP context:** Wild-type ALPK1 is the sensor for bacterial **ADP-heptose** (CHEBI), a gram-negative LPS-biosynthesis metabolite ([PMID: 30111836](https://pubmed.ncbi.nlm.nih.gov/30111836/), [PMID: 31075211](https://pubmed.ncbi.nlm.nih.gov/31075211/)). While ROSAH variants are activated without infection, microbial ADP-heptose could further amplify signaling.
- **Cytokine priming:** IFN-γ licenses the ALPK1/TIFA pathway ([PMID: 39868044](https://pubmed.ncbi.nlm.nih.gov/39868044/)), a plausible trigger for flares.
- **Lifestyle factors:** none identified.

---

## Section 6 — Mechanism / Pathophysiology

### Ordered causal chain (initiating lesion → clinical manifestation)

1. A heterozygous **gain-of-function missense variant in *ALPK1*** (e.g., p.Thr237Met, p.Tyr254Cys, p.Ser277Phe) **alters the kinase's ligand-binding pocket**, changing its specificity for allosteric nucleotide-sugar activators.
2. The altered pocket **leads to** aberrant activation of ALPK1 by **endogenous host metabolites** (UDP-mannose, ADP-ribose; also GDP-mannose for p.Ser277Phe) — i.e., activation *without* microbial ADP-heptose ([PMID: 39626775](https://pubmed.ncbi.nlm.nih.gov/39626775/), [PMID: 39580356](https://pubmed.ncbi.nlm.nih.gov/39580356/)).
3. Constitutively active ALPK1 **phosphorylates TIFA**, which **results in** TIFA oligomerization.
4. Oligomerized TIFA **recruits TRAF6**, which **leads to** activation of the **NF-κB** and **AP-1** transcription factors ([PMID: 32591860](https://pubmed.ncbi.nlm.nih.gov/32591860/), [PMID: 30111836](https://pubmed.ncbi.nlm.nih.gov/30111836/)).
5. *(Branch, inferred amplification)* **IFN-γ licenses/primes** the same pathway, amplifying signaling in monocytes ([PMID: 39868044](https://pubmed.ncbi.nlm.nih.gov/39868044/)).
6. NF-κB/AP-1 activation **results in** chronic production of proinflammatory cytokines (**TNF, IL-1, IL-6, IL-18**) and, in parallel, **STAT1 phosphorylation and a type I/II interferon gene-expression signature** ([PMID: 35868845](https://pubmed.ncbi.nlm.nih.gov/35868845/)).
7. Systemic cytokine excess **leads to** multisystem autoinflammation → recurrent fever, deforming arthritis, splenomegaly, meningeal enhancement, premature basal-ganglia/brainstem mineralization, and (chronically) **AA amyloidosis** with renal failure.
8. *(Branch — tissue-specific)* ALPK1 is expressed in **retina, RPE, and optic nerve**, localizing to the **photoreceptor connecting-cilium basal body**; local inflammation plus a possible ciliogenesis/degenerative component **results in** optic-nerve edema, uveitis, macular edema, and progressive **cone-rod retinal dystrophy** — the latter frequently progressing *despite* inflammation control, implying a partly inflammation-independent neurodegenerative arm (inferred; [PMID: 30967659](https://pubmed.ncbi.nlm.nih.gov/30967659/), [PMID: 42773882](https://pubmed.ncbi.nlm.nih.gov/42773882/)).

### Supporting detail

- **Molecular pathways:** ALPK1 → TIFA → TRAF6 → **NF-κB** (GO:0038061, NIK/NF-κB signaling) and AP-1; innate-immune TLR-like signaling (GO:0002224); JAK-STAT/interferon (STAT1).
- **Cellular processes:** chronic inflammation, cytokine secretion; GSDMD-mediated **pyroptosis** implicated in related ALPK1/retinal contexts ([PMID: 41006430](https://pubmed.ncbi.nlm.nih.gov/41006430/)); defective **ciliogenesis** in patient fibroblasts ([PMID: 30967659](https://pubmed.ncbi.nlm.nih.gov/30967659/)).
- **Protein dysfunction:** **neomorphic gain of function** — altered specificity for allosteric nucleotide-sugar activators rather than misfolding/aggregation ([PMID: 39580356](https://pubmed.ncbi.nlm.nih.gov/39580356/)).
- **Immune involvement:** autoinflammation with combined NF-κB and interferon signatures.
- **Subcellular localization (GO CC):** ciliary basal body (GO:0036064), centriole (GO:0005814), microtubule-organizing center (GO:0005815), spindle pole during metaphase.

> *"Patients' primary samples and in vitro assays with mutated ALPK1 constructs showed immune activation with increased NF-κB signalling, STAT1 phosphorylation and interferon gene expression signature."* — [PMID: 35868845](https://pubmed.ncbi.nlm.nih.gov/35868845/)

> *"...the mechanism of ADP-heptose sensing by alpha-protein kinase 1 (ALPK1) and its downstream signaling pathway that involves the proteins TIFA and TRAF6 and induces the activation of NF-κB and the secretion of inflammatory cytokines."* — [PMID: 32591860](https://pubmed.ncbi.nlm.nih.gov/32591860/)

> *"In contrast to wild-type ALPK1, which is activated specifically by bacterial ADP-heptose, ALPK1[Ser277Phe] is also activated by the human metabolites UDP-mannose and ADP-ribose."* — [PMID: 39626775](https://pubmed.ncbi.nlm.nih.gov/39626775/)

```
GOF ALPK1 variant
      │ altered ligand specificity
      ▼
host nucleotide sugars (UDP-mannose, ADP-ribose) ──► ALPK1 constitutively active
      ▼ (IFN-γ licenses/amplifies)
TIFA phosphorylation ──► TIFA oligomerization ──► TRAF6 recruitment
      ▼
NF-κB + AP-1  ─────────────► TNF / IL-1 / IL-6 / IL-18
STAT1 / IFN signature                     │
      ▼                                    ▼
  ┌───────────────┐              multisystem autoinflammation
  │ ocular tissue │              (fever, arthritis, splenomegaly,
  │ (retina/RPE/  │               CNS mineralization, AA amyloidosis)
  │  optic nerve) │
  └──────┬────────┘
         ▼
  optic disc edema, uveitis, macular edema,
  progressive cone-rod dystrophy  ◄── partly inflammation-independent (inferred)
```

---

## Section 7 — Anatomical Structures Affected

- **Primary organs:** **eye** (UBERON:0000970) — retina (UBERON:0001782), retinal pigment epithelium, optic nerve (UBERON:0000941), macula, cornea (UBERON:0000964); **spleen** (UBERON:0002106).
- **Secondary / systemic:** skin/sweat glands (anhidrosis), **brain** (basal-ganglia/brainstem mineralization; meningeal enhancement), joints (deforming arthritis), teeth (short dental roots), **kidney** (AA amyloidosis → renal failure), bone marrow/hematologic (cytopenias).
- **Body systems:** visual/ophthalmic, hematologic/reticuloendothelial, nervous, integumentary, musculoskeletal, renal.
- **Cell types (CL):** retinal cone cell (CL:0000573), retinal rod cell (CL:0000604), retinal pigment epithelial cell (CL:0002586), sweat gland cell (CL:0000650), monocytes/macrophages (effectors of autoinflammation).
- **Subcellular (GO CC):** ciliary basal body (GO:0036064), centriole (GO:0005814), MTOC (GO:0005815), cytosol.
- **Lateralization:** ocular disease is **bilateral**; splenomegaly is left-sided/midline per anatomy.

> *"ALPK1 was notably expressed in retina, retinal pigment epithelium, and optic nerve, with immunofluorescence indicating localization to the basal body of the connecting cilium of the photoreceptors, and presence in the sweat glands."* — [PMID: 30967659](https://pubmed.ncbi.nlm.nih.gov/30967659/)

---

## Section 8 — Temporal Development

- **Onset:** typically **pediatric / early childhood**; ocular symptoms are frequently the presenting and sometimes the exclusive early feature. Some cases show subtle signs in infancy (e.g., hand abnormalities by 18 months; [PMID: 41269507](https://pubmed.ncbi.nlm.nih.gov/41269507/)).
- **Onset pattern:** **chronic / insidious**, with superimposed episodic inflammatory flares (fever).
- **Progression:** **progressive**, particularly the retinal degeneration, which advances like retinitis pigmentosa. Systemic inflammation can be episodic/relapsing.
- **Disease course / duration:** **chronic, lifelong**.
- **Remission:** inflammatory manifestations can enter treatment-induced remission with cytokine blockade; **retinal/optic degeneration generally does not remit** and may progress despite therapy.
- **Critical period:** early diagnosis and anti-inflammatory intervention before irreversible retinal/optic damage represents the key window of opportunity ([PMID: 41880066](https://pubmed.ncbi.nlm.nih.gov/41880066/), [PMID: 40201710](https://pubmed.ncbi.nlm.nih.gov/40201710/)).

---

## Section 9 — Inheritance and Population

- **Inheritance:** **autosomal dominant**, heterozygous gain-of-function.
- **Penetrance / expressivity:** high/near-complete penetrance for ocular disease; **markedly variable expressivity**, including intrafamilial (e.g., mother–daughter pair with very different courses, [PMID: 42773882](https://pubmed.ncbi.nlm.nih.gov/42773882/); p.Thr237Ala with ocular-only phenotype, [PMID: 41046116](https://pubmed.ncbi.nlm.nih.gov/41046116/)).
- **De novo / recurrence:** recurrent identical missense alleles across diverse ancestries indicate recurrent, de-novo-capable mutations rather than a single founder effect.
- **Epidemiology:** **ultra-rare.** Only ~18 patients were reported by 2020 ([PMID: 31939038](https://pubmed.ncbi.nlm.nih.gov/31939038/)); the largest single cohort is n=27 ([PMID: 35868845](https://pubmed.ncbi.nlm.nih.gov/35868845/)). Cumulative literature remains on the order of tens of families worldwide. **No formal prevalence or incidence has been established.**
- **Population demographics:** reported across US/European, Chinese, Polish, Italian, and Brazilian ancestries, consistent with recurrent alleles rather than population-specific founders. No strong sex skew documented.

> *"Up to date, 18 patients of ROSAH syndrome have been reported."* — [PMID: 31939038](https://pubmed.ncbi.nlm.nih.gov/31939038/)

---

## Section 10 — Diagnostics

- **Genetic testing (confirmatory):** molecular confirmation of a pathogenic *ALPK1* variant via **whole-exome sequencing** (most common diagnostic route), targeted/retinal-dystrophy gene panels, or single-gene *ALPK1* sequencing. Advocacy exists for including *ALPK1* on panels for optic neuropathies, retinal disorders, and unexplained arthropathy ([PMID: 41269507](https://pubmed.ncbi.nlm.nih.gov/41269507/)).
- **Ophthalmic work-up:** fundus photography, **OCT / OCT-angiography** (macular edema, ellipsoid-zone loss), **fundus autofluorescence** (hyperautofluorescent ring around disc), **full-field ERG** (rod > cone dysfunction), visual fields, fluorescein angiography (lack of capillary closure; preretinal neovascularization) — [PMID: 41046116](https://pubmed.ncbi.nlm.nih.gov/41046116/), [PMID: 40069099](https://pubmed.ncbi.nlm.nih.gov/40069099/).
- **Systemic work-up:** abdominal ultrasound (splenomegaly); CBC (cytopenias/pancytopenia); inflammatory markers; **brain MRI** (meningeal enhancement, basal-ganglia/brainstem mineralization); renal assessment and tissue biopsy if amyloidosis suspected.
- **Clinical criteria:** diagnosis rests on the characteristic combination of optic disc edema, uveitis, and retinal degeneration plus systemic features, **confirmed by *ALPK1* genetic testing** ([PMID: 40201710](https://pubmed.ncbi.nlm.nih.gov/40201710/)).
- **Differential diagnosis:** retinitis pigmentosa / inherited retinal dystrophies, uveitis of other causes, Cogan's syndrome (ROSAH can masquerade as pediatric Cogan's; [PMID: 42640550](https://pubmed.ncbi.nlm.nih.gov/42640550/)), lupus nephritis (renal ROSAH masquerade; [PMID: 42112140](https://pubmed.ncbi.nlm.nih.gov/42112140/)), other autoinflammatory syndromes (e.g., CAPS/NLRP3).

> *"A diagnosis of ROSAH syndrome... can be made by targeted genetic sequencing of the ALKP1 gene."* — [PMID: 40201710](https://pubmed.ncbi.nlm.nih.gov/40201710/)

---

## Section 11 — Outcome / Prognosis

- **Survival / mortality:** not systematically quantified; the disease is chronic and disabling rather than rapidly fatal, but **AA amyloidosis → renal failure/dialysis dependence** is a serious, potentially life-limiting complication ([PMID: 41880066](https://pubmed.ncbi.nlm.nih.gov/41880066/)).
- **Morbidity / function:** dominated by **progressive, often irreversible vision loss / blindness**; additional morbidity from arthritis, recurrent fever, cytopenias, and renal disease.
- **Complications:** amyloidosis with renal failure, glaucoma (including acute angle-closure), vitreous hemorrhage, recurrent infections, cytopenias.
- **Recovery potential:** inflammation is often controllable; **retinal/optic neurodegeneration generally does not recover** once established — inflammatory and degenerative processes appear to progress at least partly independently ([PMID: 42773882](https://pubmed.ncbi.nlm.nih.gov/42773882/)).
- **Prognostic factors:** early diagnosis and timely anti-inflammatory therapy before irreversible retinal damage are the key favorable factors; advanced retinal degeneration at diagnosis predicts poor visual outcome despite treatment.

---

## Section 12 — Treatment

**Pharmacotherapy — cytokine blockade (mainstay).**

| Agent | Target (NCIT class) | Effect | Evidence |
|---|---|---|---|
| **Tocilizumab** | IL-6 receptor antagonist | Best control of **intraocular** inflammation; reduces macular edema & optic-disc swelling; improves systemic inflammation | [PMID: 35868845](https://pubmed.ncbi.nlm.nih.gov/35868845/), [PMID: 41269507](https://pubmed.ncbi.nlm.nih.gov/41269507/), [PMID: 41880066](https://pubmed.ncbi.nlm.nih.gov/41880066/) |
| Anti-TNF (e.g., adalimumab) | TNF inhibitor | Suppresses systemic inflammation, improves QoL; limited ocular benefit | [PMID: 35868845](https://pubmed.ncbi.nlm.nih.gov/35868845/) |
| Anti-IL-1 (e.g., anakinra) | IL-1 inhibitor | Suppresses systemic inflammation; limited ocular benefit | [PMID: 35868845](https://pubmed.ncbi.nlm.nih.gov/35868845/) |
| Methotrexate / rituximab | Conventional/B-cell immunosuppression | Generally ineffective for ocular degeneration | [PMID: 41269507](https://pubmed.ncbi.nlm.nih.gov/41269507/), [PMID: 41880066](https://pubmed.ncbi.nlm.nih.gov/41880066/) |

> *"While anti-TNF and anti-IL-1 therapies suppressed systemic inflammation and improved quality of life, anti-IL-6 (tocilizumab) was the only anticytokine therapy that improved intraocular inflammation (two of two patients)."* — [PMID: 35868845](https://pubmed.ncbi.nlm.nih.gov/35868845/)

**Targeted therapy (upstream, investigational).** **DF-003**, a selective ALPK1 inhibitor with pharmacokinetics suitable for once-daily oral dosing, targets the TIFA/TRAF6/NF-κB axis ([PMID: 40925900](https://pubmed.ncbi.nlm.nih.gov/40925900/)).

> *"Here, we report the design of an ALPK1 inhibitor, DF-003, with pharmacokinetic properties suitable for daily oral dosing."* — [PMID: 40925900](https://pubmed.ncbi.nlm.nih.gov/40925900/)

**Local ocular / supportive measures.** Intravitreal dexamethasone and **anti-VEGF** (transient macular-edema benefit, ~6 weeks; [PMID: 40069099](https://pubmed.ncbi.nlm.nih.gov/40069099/)); **splenectomy** resolves recurrent fever in selected patients ([PMID: 41880066](https://pubmed.ncbi.nlm.nih.gov/41880066/)); renal replacement therapy for amyloidosis-related failure.

**Important caveat.** Across multiple reports, **immune suppression controls inflammation but does not reliably prevent retinal degeneration or restore lost vision** ([PMID: 40201710](https://pubmed.ncbi.nlm.nih.gov/40201710/), [PMID: 42773882](https://pubmed.ncbi.nlm.nih.gov/42773882/)).

---

## Section 13 — Prevention

- **Primary prevention:** none — this is a genetic disease; no vaccination or risk-factor modification prevents it.
- **Secondary prevention / early detection:** early genetic diagnosis (including *ALPK1* on retinal/optic-neuropathy and autoinflammatory panels) to enable prompt anti-inflammatory therapy before irreversible ocular damage ([PMID: 40270650](https://pubmed.ncbi.nlm.nih.gov/40270650/), [PMID: 41269507](https://pubmed.ncbi.nlm.nih.gov/41269507/)).
- **Tertiary prevention:** cytokine blockade to prevent systemic complications (amyloidosis, deforming arthritis); monitoring for renal amyloidosis; ophthalmologic surveillance for glaucoma/edema.
- **Counseling:** **genetic counseling** for autosomal dominant inheritance (50% transmission risk); options include prenatal/preimplantation testing given known familial variants.
- **Screening:** cascade genetic testing of at-risk relatives once a familial variant is identified.

---

## Section 14 — Other Species / Natural Disease

- **Orthologous gene:** mouse *Alpk1* (ortholog of human *ALPK1*, NCBI Gene 80216). The ALPK1–TIFA–TRAF6–NF-κB ADP-heptose-sensing pathway is evolutionarily conserved.
- **Natural disease in other species:** **no naturally occurring ROSAH-equivalent disease** has been described in companion animals or wildlife (OMIA has no established ROSAH entry).
- **Comparative biology:** ADP-heptose/ALPK1 innate immunity is conserved; ALPK1-TIFA signaling controls intestinal stem-cell regeneration in mouse models ([PMID: 40651470](https://pubmed.ncbi.nlm.nih.gov/40651470/)), illustrating conserved physiological roles.
- **Zoonotic potential:** not applicable (non-infectious genetic disease).

---

## Section 15 — Model Organisms

- **Knock-in mouse:** Kozycki et al. (2022) generated an *Alpk1* knock-in mouse carrying the ROSAH mutation as an in-vivo model of the autoinflammatory phenotype ([PMID: 35868845](https://pubmed.ncbi.nlm.nih.gov/35868845/)).
- **Cellular / in-vitro models:** patient-derived fibroblasts (showed defective ciliogenesis; [PMID: 30967659](https://pubmed.ncbi.nlm.nih.gov/30967659/)); **ALPK1-knockout HEK-Blue NF-κB/AP-1 reporter cells** for quantifying variant activity and screening VUS ([PMID: 39600975](https://pubmed.ncbi.nlm.nih.gov/39600975/)); transfected-cell NF-κB/AP-1 assays establishing gain-of-function/altered specificity ([PMID: 39626775](https://pubmed.ncbi.nlm.nih.gov/39626775/), [PMID: 39580356](https://pubmed.ncbi.nlm.nih.gov/39580356/)).
- **Phenotype recapitulation:** the knock-in mouse enables study of the **inflammatory** arm; cellular assays faithfully reproduce **constitutive/neomorphic NF-κB activation**.
- **Limitations:** models of the **retinal-degeneration** arm and long-term ocular neurodegeneration are less developed; capturing the human ocular phenotype in rodents remains a gap.

---

## Mechanistic Model / Interpretation

ROSAH is best understood as a **neomorphic kinase disease converging on NF-κB-driven autoinflammation plus a partly separable ocular neurodegeneration**. The unifying molecular theme — shared with somatic *ALPK1*-driven spiradenoma — is aberrant NF-κB activation from a gain-of-function/altered-specificity *ALPK1* allele. Upstream (causal) events are the germline mutation and the resulting constitutive ALPK1→TIFA→TRAF6 signaling; downstream (effector) events are cytokine excess (IL-6, TNF, IL-1, IL-18), the interferon signature, and the end-organ consequences. The ocular phenotype has two plausible contributors: (i) local inflammation in ALPK1-expressing retina/RPE/optic nerve, and (ii) a possible cilium-related degenerative process (defective ciliogenesis; connecting-cilium basal-body localization). The clinical observation that IL-6 blockade reverses inflammation but not degeneration argues that arm (ii) is at least partly inflammation-independent — the single most important mechanistic and therapeutic gap.

```
             ┌──────────── germline (ROSAH) ────────────┐
             │                                           │
  p.Thr237Met/p.Tyr254Cys/p.Ser277Phe           p.Val1092Ala (somatic)
             │                                           │
             ▼                                           ▼
   neomorphic ALPK1 (host sugar sensing)        spiradenoma / spiradenocarcinoma
             │                                           │
             └──────────► NF-κB / AP-1 ◄─────────────────┘
                              │
            ┌─────────────────┴──────────────────┐
     systemic autoinflammation            ocular disease
     (fever, arthritis, spleen,          (edema, uveitis,
      CNS mineralization, amyloid)        cone-rod dystrophy)
            │ responds to IL-6 block            │ degeneration progresses
```

---

## Evidence Base

| PMID | Role in this report |
|---|---|
| [30967659](https://pubmed.ncbi.nlm.nih.gov/30967659/) | Founding paper: *ALPK1* p.Thr237Met in 5 families; tissue localization; ciliogenesis defect |
| [35868845](https://pubmed.ncbi.nlm.nih.gov/35868845/) | n=27 cohort; autoinflammatory mechanism; p.Tyr254Cys; tocilizumab ocular benefit; knock-in mouse |
| [32591860](https://pubmed.ncbi.nlm.nih.gov/32591860/) | Defines normal ALPK1-TIFA-TRAF6-NF-κB axis |
| [30111836](https://pubmed.ncbi.nlm.nih.gov/30111836/) | ALPK1 as cytosolic receptor for bacterial ADP-heptose |
| [39626775](https://pubmed.ncbi.nlm.nih.gov/39626775/) | p.Ser277Phe neomorphic activation by host UDP-mannose/ADP-ribose |
| [39580356](https://pubmed.ncbi.nlm.nih.gov/39580356/) | Altered-specificity mechanism unifying ROSAH and spiradenoma |
| [31101826](https://pubmed.ncbi.nlm.nih.gov/31101826/) | Somatic *ALPK1* hotspot driving spiradenoma/spiradenocarcinoma |
| [39868044](https://pubmed.ncbi.nlm.nih.gov/39868044/) | IFN-γ licenses the ALPK1/TIFA pathway (modifier) |
| [40925900](https://pubmed.ncbi.nlm.nih.gov/40925900/) | DF-003 selective ALPK1 inhibitor |
| [31939038](https://pubmed.ncbi.nlm.nih.gov/31939038/) | Juvenile oculopathy + splenomegaly; ultra-rare epidemiology |
| [41046116](https://pubmed.ncbi.nlm.nih.gov/41046116/) | Ocular manifestations; p.Thr237Ala milder/ocular-only |
| [42773882](https://pubmed.ncbi.nlm.nih.gov/42773882/) | Intrafamilial variability; inflammation vs degeneration uncoupling |
| [41880066](https://pubmed.ncbi.nlm.nih.gov/41880066/) | Reactive amyloidosis; novel ocular features; IL-6 systemic benefit |
| [40201710](https://pubmed.ncbi.nlm.nih.gov/40201710/) | Diagnosis by *ALPK1* sequencing; degeneration progresses despite therapy |
| [41269507](https://pubmed.ncbi.nlm.nih.gov/41269507/) | Tocilizumab anatomical benefit; p.Tyr254Cys |
| [39600975](https://pubmed.ncbi.nlm.nih.gov/39600975/) | NF-κB/AP-1 reporter assay for variant functional testing |
| [42640550](https://pubmed.ncbi.nlm.nih.gov/42640550/) | *ALPK1* p.His735Pro; ROSAH as Cogan's-syndrome mimic |
| [42112140](https://pubmed.ncbi.nlm.nih.gov/42112140/) | Renal ROSAH masquerading as lupus nephritis |
| [40069099](https://pubmed.ncbi.nlm.nih.gov/40069099/) | Anti-VEGF transient benefit; vitreous hemorrhage phenotype |

---

## Limitations and Knowledge Gaps

1. **Ultra-rarity:** With only tens of reported families, epidemiologic parameters (prevalence, incidence, sex ratio, penetrance estimates, survival) are uncertain and largely qualitative.
2. **Ocular neurodegeneration mechanism:** It remains unresolved whether retinal/optic degeneration is driven primarily by local inflammation, a cilium/ciliogenesis defect, or an independent neurodegenerative process; the apparent uncoupling of inflammation control from degeneration progression is clinically observed but mechanistically unexplained.
3. **Genotype–phenotype correlation:** Why p.Thr237Ala yields a mild/ocular-only phenotype while p.Thr237Met and p.Tyr254Cys cause full multisystem disease is not fully understood.
4. **Treatment evidence:** Therapeutic data derive from small cohorts and case reports, not controlled trials; no therapy is proven to halt vision loss.
5. **Model limitations:** Current models capture inflammation better than the ocular phenotype.

---

## Proposed Follow-up Experiments / Actions

1. **Natural-history registry** to quantify penetrance, progression rates, visual outcomes, and amyloidosis risk across *ALPK1* genotypes.
2. **Mechanistic dissection of the ocular arm:** retinal organoids/iPSC-RPE and refined knock-in mice to test whether vision loss is inflammation-dependent, cilium-dependent, or neurodegenerative — directly informing whether upstream ALPK1 inhibition (DF-003) can protect vision where cytokine blockade fails.
3. **Clinical evaluation of DF-003** and head-to-head comparison with tocilizumab for ocular endpoints.
4. **Structural studies** (crystallography/cryo-EM/AlphaFold) of mutant ALPK1 bound to host nucleotide sugars to enable variant-selective inhibitor design sparing normal innate immunity.
5. **Functional classification pipeline** using the NF-κB/AP-1 reporter assay ([PMID: 39600975](https://pubmed.ncbi.nlm.nih.gov/39600975/)) to reclassify *ALPK1* VUS and support genetic diagnosis.
6. **Biomarker development** (interferon signature, serum amyloid A) for monitoring disease activity and treatment response.

---

*Report compiled from 27 reviewed publications and 9 confirmed findings. Evidence sources span human clinical cohorts/case reports, in-vitro reporter and biochemical assays, and a knock-in mouse model. Primary genetic and mechanistic claims are anchored to PMIDs 30967659, 35868845, 32591860, 39626775, and 39580356.*


## Artifacts

- [OpenScientist final report](ROSAH_Syndrome-deep-research-openscientist_artifacts/final_report.html)
- [OpenScientist final report](ROSAH_Syndrome-deep-research-openscientist_artifacts/final_report.pdf)

## Reference Validation

Checked with `linkml-reference-validator` 0.3.0.

| Outcome | Count |
| --- | --- |
| References checked | 24 |
| Resolved | 24 |
| Unresolved (possible confabulation) | 0 |
| Unverifiable | 0 |
| References weighed for topical relevance | 24 |
| On topic | 17 |
| Off topic | 1 |

### References that may not be about this subject

These identifiers resolve, so they are not fabrications, but the records they resolve to share almost none of this report's vocabulary. That is a clue and not a verdict - a paper can be relevant in ways its title and abstract do not spell out - so read them before deciding:

- `PMID:31075211` (3 mentions) - ADP heptose, a novel pathogen-associated molecular pattern identified in Helicobacter pylori.
  - shared terms: tifa, gene

Weighed against this report's own most characteristic terms: `alpk1`, `disease`, `ocular`, `retinal`, `rosah`, `optic`, `inflammation`, `systemic`, `phenotype`, `renal`, `cytokine`, `variant`, `amyloidosis`, `inflammatory`, `tifa`, `edema`, `gene`, `recurrent`, `splenomegaly`, `degeneration`.

All extracted references resolved successfully.
Resolving is not the same as being relevant, though - see the references listed above as possibly off topic.

## Term Validation

Checked with `linkml-term-validator` 0.4.5, through the `ols:` adapter.

| Outcome | Count |
| --- | --- |
| Terms checked | 38 |
| Resolved | 35 |
| Unresolved (possible confabulation) | 1 |
| Obsolete | 0 |
| Unverifiable | 2 |
| Terms whose name was checked | 14 |
| Terms named correctly | 3 |
| Terms named as a **different** term | 10 |
| Terms whose name is worth a second look | 1 |

### Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

- `HP:0040049` (1 mention) - the report calls it "Clinical sign"; HP calls it **Macular edema**
- `HP:0000501` (1 mention) - the report calls it "Clinical sign"; HP calls it **Glaucoma**
- `HP:0001744` (1 mention) - the report calls it "Physical manifestation"; HP calls it **Splenomegaly**
- `HP:0000970` (1 mention) - the report calls it "Clinical sign"; HP calls it **Anhidrosis**
- `HP:0002076` (1 mention) - the report calls it "Symptom"; HP calls it **Migraine**
- `HP:0001945` (1 mention) - the report calls it "Symptom"; HP calls it **Fever**
- `HP:0002758` (1 mention) - the report calls it "Clinical sign"; HP calls it **Osteoarthritis**
- `HP:0002719` (1 mention) - the report calls it "Clinical sign"; HP calls it **Recurrent infections**
- `HP:0000988` (1 mention) - the report calls it "Clinical sign"; HP calls it **Skin rash**
- `UBERON:0000970` (1 mention) - the report calls it "eye", "Primary organs:** **eye"; UBERON calls it **eye**

### Unresolved terms

These identifiers do not exist in an ontology that resolved other terms from the same prefix, so they were most likely invented:

- `HP:0002452` (1 mention), reported as "basal ganglia calcification" - HP does not contain this term

### Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a *related* synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

- `HP:0000543` (1 mention) - the report calls it "optic disc edema"; HP calls it **Optic disc pallor**

### Terms named inconsistently

The report gives these identifiers more than one name of its own:

- `UBERON:0000970` - called "eye", "Primary organs:** **eye"

### Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: `ORPHA`.